Key Press Releases

Q-Sera Pty Ltd and JHL Biotech, Inc. announce a strategic collaboration

May 21, 2020

Q-Sera Pty Ltd is pleased to announce a collaboration with JHL Biotech, Inc. (Taiwan) to produce high yielding recombinant ecarin for commercial scale production of RAPClot™ Rapid Serum tubes.

Q-Sera has developed a superior serum/blood clotting tube, RAPClot TM Rapid Serum tube, for widespread use in hospitals and pathology labs. The tubes use a novel class of patented coagulation agents to rapidly clot blood samples to produce serum for analysis. These proteins, found in the venom of some of the world’s deadliest snakes can now be produced at commercial scale from modified cell lines developed by JHL Biotech using standard biotech manufacturing processes.

RAPClot TM Rapid Serum blood collection tubes are coated with RAPClot™, recombinant ecarin, resulting in tubes which rapidly produce high quality serum, including for blood samples that contain anti-coagulants. These benefits will provide cost efficiencies for healthcare systems and improved outcomes for patients.

JHL Biotech, Inc. has developed a number of proprietary cell lines and associated protein expression technologies to enable Q-Sera to produce its recombinant ecarin, RAPClot™, in higher yields. The companies have been collaborating under JHL’s partnering program in which it works with companies on products with disruptive potential such as Q-Sera’s RAPClot TM Rapid Serum tube.

Michael Grant, CEO of Q-Sera, said, “JHL Biotech’s proprietary technology has already been able to demonstrate that we can achieve high yield and low cost production of recombinant ecarin for use in our blood clotting tubes. This is potentially disruptive as Q-Sera seeks to provide a superior replacement for current serum and plasma tubes with the RAPClot™ Rapid Serum tube.”

Download PDF

Q-Sera’s innovative blood clotting technology granted patent in US

August 19, 2019

Medical device company Q-Sera Pty Ltd today announces that it has received a Notice of Allowance from the United States Patent & Trademark Office for the foundation patent of its innovative blood clotting technology for use in blood collection tubes.

Q-Sera’s technology now has patent protection for use in blood collection tubes in the United States, Europe, Japan, China, Mexico, Russia, Canada, South Africa and Australia. Q-Sera is progressing additional patents to cover novel formulations and expanded uses for its unique actives, extending the commercial opportunities.

Read more

International Expert in Blood Collection Tubes joins Q-Sera

October 2, 2018

Q-Sera Pty Ltd (Q-Sera) is pleased to announce the addition of international consultant and expert in the field of blood collection tubes, Franz E. Kirchmeir to our growing company to further R&D efforts and assist in the commercialization of the RAPClot™ technology.

Franz was previously the Director of Business Development at Greiner Bio-One Preanalytics at their global headquarters in Austria. He brings 20 years’ experience in the pre-analytical business sector including blood collection tubes, as well as extensive knowledge in R&D management, business development and strategic management. Q-Sera is pleased to welcome Franz to the team to help bring our technology into international markets.

Read more

Q-Sera’s innovative blood clotting technology patent granted in China

November 27, 2017

Q-Sera Pty Ltd (Q-Sera) is pleased to announce that the foundation patent for its innovative blood clotting technology, RAPClot™, has been granted in China which joins a growing list of countries where the patent has now been granted which include the EU, Japan and Australia.

Read more

Q-Sera’s innovative blood clotting technology presented at leading international scientific conference

October 23, 2017

A poster presentation on Q-Sera’s recombinant prothrombin activator RAPClot™ technology for blood collection tubes was made at the 23rd International Congress of Clinical Chemistry and Laboratory Medicine (IFCC Worldlab) in Durban, South Africa.

Read more

Publications

Zhao et al, Rapid serum tube technology overcomes problems associated with use of anticoagulants. BioMedica 2019;29(3):1-17.
 
Zhao et al, Next-generation rapid serum tube technology using prothrombin activator coagulant: fast, high quality serum from normal samples. Clin Chem Lab Med 2019 Mar 26; 57(4):483-497.